In comments submitted Saturday, AHA generally supports the Centers for Medicare & Medicaid Services’ initial guidance implementing inflation rebates for certain single source drugs and biosimilar biological products covered by Medicare Part B, but recommends changes to prevent incentivizing drug shortages and burdening 340B hospitals. Drug units purchased under the 340B program are not subject to the Inflation Reduction Act rebates.

Related News Articles

Headline
Senate Finance Committee Chair Ron Wyden, D-Ore., and Ranking Member Mike Crapo, R-Idaho, released a white paper May 17 outlining policy concepts regarding pay…
Headline
The RAND Corporation May 13 released its latest hospital pricing report, which focuses on prices paid for care at the hospital and service-line level. In…
Headline
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price…
Headline
The Medicare Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2036, according to the latest annual report by the Medicare…
Headline
The departments of Health and Human Services, Labor, and the Treasury May 1 released a new process for resubmitting disputes under the No Surprises Act…
Headline
Eleven organizations representing health care providers, including the AHA, April 29 urged the Centers for Medicare & Medicaid Services not to hold…